| Bioactivity | NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI)[1]. |
| Invitro | NF-κB-IN-15 (compound 14r) (1.25, 2.5, 5, 10, 20 µM; 1+24 h) 在LPS 诱导的 RAW 264.7 细胞中以剂量依赖性方式降低 NO 水平并抑制 IL-6、TNF-α、IL-1β[1]。NF-κB-IN-15（10、20 µM；1+4 h） 抑制 LPS 诱导的 p65 磷酸化和 IκBα 的降解[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> NF-κB-IN-15 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | NF-κB-IN-15 (compound 14r) (20 mg/kg; i.p.) 在急性肺损伤 (ALI) 小鼠中显示出抗炎活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C46H58N4O8 |
| Molar Mass | 794.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang J, et al. Total synthesis and structural modification of the dibenzylbutane lignan LCA as a potent anti-inflammatory agent against LPS-induced acute lung injury. Eur J Med Chem. 2024 Feb 20;268:116272. |